Drug Shortage Active
TIGLUTIK KIT is currently in shortage. Reason: Unavailable. This may impact manufacturing, supply chain, and quality hiring at the manufacturer.
TIGLUTIK KIT (riluzole) by Italfarmaco Research is 12. Approved for amyotrophic lateral sclerosis. First approved in 2018.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
TIGLUTIK KIT is an oral suspension formulation of riluzole, a benzothiazole small molecule indicated for amyotrophic lateral sclerosis (ALS). The mechanism of action remains unknown, though riluzole is believed to modulate neuronal excitability in ALS patients. This is a re-formulation of the original tablet-based RILUTEK, designed for improved patient administration.
TIGLUTIK is approaching loss of exclusivity (LOE) in 2.9 years, signaling a contraction phase requiring defensive positioning and likely reduced team investment as generic competition emerges.
12.1 Mechanism of Action The mechanism by which riluzole exerts its therapeutic effects in patients with ALS is unknown. 12.2 Pharmacodynamics The clinical pharmacodynamics of riluzole has not been determined in humans. 12.3 Pharmacokinetics Table 2 displays the pharmacokinetic parameters of…
Benzothiazole
Worked on TIGLUTIK KIT at Italfarmaco Research? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Safety of Intrathecal Riluzole in Patients With Amyotrophic Lateral Sclerosis
Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in Chinese Healthy Subject
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets
Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~3 years — strategic planning for patent cliff underway
TIGLUTIK offers limited career growth opportunities given approaching LOE, current supply shortages, and zero linked job openings. Positions on this product are primarily defensive, focused on managing market share decline and supporting generic transition rather than driving innovation or market expansion.